RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

Shomali, Navid; Maashi, Marwah Suliman; Baradaran, Behzad; Sorkhabi, Amin Daei; Sarkesh, Aila; Mohammadi, Hamed; Hemmatzadeh, Maryam; Marofi, Faroogh; Shotorbani, Siamak Sandoghchian; Jarahian, Mostafa

doi:10.3389/fimmu.2022.839945

Cited by 22 publications

(14 citation statements)

References 121 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They revealed that miR-34a delivered by GC4-targeted nanoparticles significantly reduced tumor load in the lung and downregulated expression of survivin in the metastatic tumor [227]. Survivin, an antiapoptotic factor that has been identified as a therapeutic target in a variety of disorders, plays a crucial part in mechanisms that promote tumor development and angiogenesis [228]. HIF1α stability in low oxygen environments and/or through ROS generation enhances survivin and VEGF expression and angiogenesis [229,230].…”

Section: Lipid-based Vectorsmentioning

confidence: 99%

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

Yang

Zhang

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

After skin malignancy, breast cancer is the most widely recognized cancer detected in women in the United States. Breast cancer (BCa) can happen in all kinds of people, but it's much more common in women. One in four cases of cancer and one in six deaths due to cancer are related to breast cancer. Angiogenesis is an essential factor in the growth of tumors and metastases in various malignancies. An expanded level of angiogenesis is related to diminished endurance in BCa patients. This function assumes a fundamental part inside the human body, from the beginning phases of life to dangerous malignancy. Various factors, referred to as angiogenic factors, work to make a new capillary. Expanding proof demonstrates that angiogenesis is managed by microRNAs (miRNAs), which are small non-coding RNA with 19–25 nucleotides. MiRNA is a post-transcriptional regulator of gene expression that controls many critical biological processes. Endothelial miRNAs, referred to as angiomiRs, are probably concerned with tumor improvement and angiogenesis via regulation of pro-and anti-angiogenic factors. In this article, we reviewed therapeutic functions of miRNAs in BCa angiogenesis, several novel delivery carriers for miRNA-based therapeutics, as well as CRISPR/Cas9 as a targeted therapy in breast cancer.

show abstract

Section: Lipid-based Vectorsmentioning

confidence: 99%

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

Yang

Zhang

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“… 40 Just recently, several microRNAs have been implicated in survivin regulation which may downregulate anti-apoptotic survivin expression in apoptotic cells or, in opposite direction, contribute to survivin upregulation, enhancing their sustained activation and autoreactivity in autoreactive immune cells. 42 …”

Section: Discussionmentioning

confidence: 99%

The Behaviour of Serum Survivin in Patients With Lupus Nephritis

et al. 2022

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is a chronic, multi phenotypic, autoimmune inflammatory disease and renal involvement significantly worsens its prognosis. Apoptosis dysregulation plays a key pathogenic role. Survivin, a protein from the apoptosis inhibitors family, has been considered a promising strategy in cancer therapy and evaluated as one of the regulatory pathways in the scenario of immune-mediated disorders. Objective: This study aims to explore survivin behaviour in SLE patients with lupus nephritis (LN), assessing its potential as a therapeutic and prognostic biomarker. Methods: 297 SLE patients were classified based on the American College of Rheumatology (ACR) 1997 criteria, from 2000 to 2015. In a cross-sectional study, the serum level of survivin was measured by an ELISA test and compared between 200 SLE individuals and healthy controls. In a longitudinal cohort, 97 patients with active LN had the concentration of survinin measured, before and after treatment with cyclophosphamide pulse therapy. Results: The serum concentration of survivin was significantly lower in the SLE group than in healthy controls, regardless of concomitant NL or disease activity. The longitudinal evaluation revealed a significant reduction in survivin serum level after treatment. However, survivin rates were not able to discriminate groups that achieved remission from those that maintained nephritis activity. Conclusion: Our study suggests that survivin levels in SLE patients are lower than in the general population. Even so, its use as a biomarker in SLE seems limited, not reflecting disease activity or response to LN treatment, as in other contexts.

show abstract

“…Their results revealed that cells and tumors have increased expression of survivin and cell surface proteins which provide effective OV entry and replication in DIPG cells and result in more prolonged survival [ 179 ]. To elaborate, survivin is an anti-apoptotic factor that facilitates the viability and survival of cells and has been identified as a target in the treatment of several autoimmune diseases and cancers [ 180 , 181 ].…”

Section: Msc-based Delivery Of Oncolytic Adenovirus (Oads)mentioning

confidence: 99%

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

et al. 2023

View full text Add to dashboard Cite

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no damage to normal cells in the process. Because of their specific features, such as, the ability to induce immunogenic cell death and to contain curative transgenes in their genomes, OVs have attracted attention as candidates to be utilized in cooperation with immunotherapies for cancer treatment. This treatment takes advantage of most tumor cells' inherent tendency to be infected by certain OVs and both innate and adaptive immune responses are elicited by OV infection and oncolysis. OVs can also modulate tumor microenvironment and boost anti-tumor immune responses. Mesenchymal stem cells (MSC) are gathering interest as promising anti-cancer treatments with the ability to address a wide range of cancers. MSCs exhibit tumor-trophic migration characteristics, allowing them to be used as delivery vehicles for successful, targeted treatment of isolated tumors and metastatic malignancies. Preclinical and clinical research were reviewed in this study to discuss using MSC-released OVs as a novel method for the treatment of cancer.

show abstract

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

Cited by 22 publications

References 121 publications

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

The Behaviour of Serum Survivin in Patients With Lupus Nephritis

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

Contact Info

Product

Resources

About